State Street Corp ownership in CPRX / Catalyst Pharmaceuticals, Inc.

催化劑製藥公司

US ˙ NasdaqCM ˙ US14888U1016

Security	CPRX / Catalyst Pharmaceuticals, Inc.
Institution	State Street Corp
Latest Disclosed Ownership	6,405,387 shares
Ownership	5.20%

2025-11-10 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,405,387 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX). This represents 5.2 percent ownership of the company. In their previous filing dated 2024-10-17 , State Street Corp had reported owning 5,685,330 shares, indicating an increase of 12.67 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2025-11-10	2025-11-10	13G	5,685,330	6,405,387	12.67	5.20	8.33
2024-10-17	2024-10-17	13G/A	6,787,332	5,685,330	-16.24	4.80	-24.65
2024-01-25	2024-01-25	13G/A	7,873,314	6,787,332	-13.79	6.37	-15.85
2023-02-08	2023-02-08	13G/A	5,050,989	7,873,314	55.88	7.57	54.49
2022-02-09	2022-02-09	13G/A	6,113,930	5,050,989	-17.39	4.90	-16.95
2021-02-05	2021-02-05	13G	7,418,295	6,113,930	-17.58	5.90	-18.06
2020-02-14	2020-02-14	13G		7,418,295		7.20

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	6,863,060	-44,562	-0.65	169,929	5.40	0.0059
2026-02-13	2025-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	6,907,622	502,235	7.84	161,224	27.77	0.0054
2025-11-14	2025-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	6,405,387	926,999	16.92	126,186	6.14	0.0044
2025-08-14	2025-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	5,478,388	-52,049	-0.94	118,881	-11.36	0.0045
2025-05-15	2025-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	5,530,437	-266,123	-4.59	134,113	10.86	0.0055
2025-02-14	2024-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	5,796,560	111,230	1.96	120,974	7.03	0.0048
2024-11-14	2024-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	5,685,330	-347,968	-5.77	113,024	20.94	0.0046
2024-08-14	2024-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	6,033,298	-2,119,604	-26.00	93,456	-28.09	0.0041
2024-05-15	2024-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	8,152,902	1,365,570	20.12	129,957	13.90	0.0058
2024-02-14	2023-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	6,787,332	-783,363	-10.35	114,095	28.92	0.0055
2023-11-14	2023-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	7,570,695	-1,882,382	-19.91	88,501	-30.34	0.0049
2023-08-14	2023-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	9,453,077	1,910,359	25.33	127,049	1.59	0.0067
2023-05-15	2023-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	7,542,718	-330,596	-4.20	125,058	-14.60	0.0071
2023-05-15	2022-12-31	13F/A-99	CATALYST PHARMACEUTICALS	COM	14888U101	7,873,314	317,891	4.21	146,444	51.07	0.0086
2023-05-15	2022-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	7,873,314	317,891		146,444		0.0086
2022-11-15	2022-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	7,555,423	2,117,944	38.95	96,936	154.31	0.0061
2022-08-15	2022-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	5,437,479	819,524	17.75	38,117	-0.43	0.0023
2022-05-16	2022-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	4,617,955	-433,034	-8.57	38,283	11.95	0.0019
2022-02-14	2021-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	5,050,989	-1,018,392	-16.78	34,195	6.30	0.0016
2021-11-15	2021-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	6,069,381	70,933	1.18	32,168	-6.74	0.0017
2021-08-16	2021-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	5,998,448	-2,935,535	-32.86	34,491	-16.26	0.0018
2021-07-09	2021-03-31	13F/A-1	CATALYST PHARMACEUTICALS	COM	14888U101	8,933,983	2,820,053	46.13	41,186	101.68	0.0024
2021-05-17	2021-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	8,933,983	2,820,053		41,186		0.0024
2021-02-16	2020-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	6,113,930	-1,518,422	-19.89	20,421	-9.91	0.0013
2020-11-10	2020-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	7,632,352	955,751	14.31	22,668	-26.51	0.0015
2020-08-14	2020-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	6,676,601	-764,221	-10.27	30,846	7.68	0.0022
2020-06-19	2020-03-31	13F/A-1	CATALYST PHARMACEUTICALS	COM	14888U101	7,440,822	22,527	0.30	28,647	2.98	0.0025
2020-05-11	2020-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	7,440,822	22,527		28,647		2,515.7834
2020-02-06	2019-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	7,418,295	3,791,669	104.55	27,819	44.46	0.0019
2019-11-14	2019-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	3,626,626	1,805,435	99.13	19,257	175.38	0.0014
2019-08-14	2019-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	1,821,191	194,096	11.93	6,993	-15.73	0.0005
2019-05-15	2019-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	1,627,095	71,118	4.57	8,298	177.80	0.0006
2019-02-12	2018-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	1,555,977	28,527	1.87	2,987	-48.26	0.0003
2018-11-09	2018-09-30	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	1,527,450	88,522	6.15	5,773	28.60	0.0004
2018-08-14	2018-06-30	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	1,438,928	235,288	19.55	4,489	56.08	0.0004
2018-05-15	2018-03-31	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	1,203,640	65,842	5.79	2,876	-35.39	0.0002
2018-02-14	2017-12-31	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	1,137,798	193,503	20.49	4,451	86.86	0.0004
2017-11-14	2017-09-30	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	944,295	6,100	0.65	2,382	-8.03	0.0002
2017-08-14	2017-06-30	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	938,195	892,895	1,971.07	2,590	2,843.18	0.0002
2017-05-15	2017-03-31	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	45,300	0	0.00	88	87.23	0.0000
2017-02-09	2016-12-31	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	45,300	0	0.00	47	-4.08	0.0000
2017-01-13	2016-09-30	13F/A-1	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	45,300	0	0.00	49	48.48	0.0000
2016-11-14	2016-09-30	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	45,300			49
2016-08-12	2016-06-30	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	45,300	-1,148,674	-96.21	33	-97.63	0.0000
2016-05-20	2016-03-31	13F/A-1	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	1,193,974	61,345	5.42	1,395	-49.77	0.0002
2016-05-12	2016-03-31	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	1,193,974			1,395
2016-02-16	2015-12-31	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	1,132,629	102,198	9.92	2,777	-10.27	0.0003
2015-11-16	2015-09-30	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	1,030,431	369,172	55.83	3,095	13.33	0.0004
2015-08-13	2015-06-30	13F	CATALYST PHARMACEUTICALS	Common equity shares	14888U101	661,259	616,859	1,389.32	2,731	1,315.03	0.0003
2015-05-15	2015-03-31	13F	CATALYST PHARM PARTNERS	Common equity shares	14888U101	44,400	0	0.00	193	45.11	0.0000
2015-02-11	2014-12-31	13F	CATALYST PHARM PARTNERS	Common equity shares	14888U101	44,400	-5,000	-10.12	133	-18.90	0.0000
2014-11-12	2014-09-30	13F/A-1	CATALYST PHARM PARTNERS	Common equity shares	14888U101	49,400	2,200	4.66	164	36.67	0.0000
2014-11-10	2014-09-30	13F	CATALYST PHARM PARTNERS	Common equity shares	14888U101	49,400			164
2014-08-12	2014-06-30	13F	CATALYST PHARM PARTNERS	Common equity shares	14888U101	47,200	0	0.00	120	12.15	0.0000
2014-05-15	2014-03-31	13F/A-1	CATALYST PHARM PARTNERS	Common equity shares	14888U101	47,200	0	0.00	107	16.30	0.0000
2014-05-13	2014-03-31	13F	CATALYST PHARM PARTNERS	Common equity shares	14888U101	47,200			107
2014-02-06	2013-12-31	13F/A-1	CATALYST PHARM PARTNERS	Common equity shares	14888U101	47,200	47,200		92		0.0000

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.